Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of 14C-labeled ASP1707 in Healthy Males
NCT02106780Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2011
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of opigolix in endometriosis, rheumatoid arthritis (RA) and prostate cancer (PCa), sponsored by Astellas Pharma. Primary endpoints: Radioactivity in whole blood measured by Area under the plasma concentration - to time = infinity, Radioactivity in whole blood measured by Area under the plasma concentration - time curve to the last quantifiable concentration and 28 more. Started Aug 2011; status: completed.
02
Drugs
opigolix
03
Conditions
endometriosisrheumatoid arthritis (RA)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02106780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02106780.